Amit Patel🇬🇧
Last synced from Twitter 87d ago
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis
The high response rates after anti-CD19 CAR T-cell therapy can be used to guide the
use of therapy in patients with relapsed or refractory acute lymphocytic leukaemia.
Comparison studies are required to further determine differences in efficacy...
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial | Blood Advances | American Society of Hematology
Key Points. Midostaurin significantly improves event-free survival in patients with FLT3-TKD mutated AML.NPM1 mutations and CBF rearrangements were favorable i
First CAR-T cell medicine for mantle lymphoma - European Medicines Agency
First CAR-T cell medicine for mantle lymphoma
HLA-A alleles influencing NK cell function impact AML relapse following allogeneic hematopoietic cell transplantation | Blood Advances | American Society of Hematology
Key Points. HLA-A*24 and HLA-A*32 inhibit KIR3DL1+ NK cells and contribute to NK education.The combination of donor KIR3DL1 and HLA-A*24 is associated with hig
Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells
A genome-wide association study identifies 17 genetic loci that are associated with the risk of myeloproliferative neoplasms (MPNs), and shows that the modulation of haematopoietic stem cell function drives MPN risk.
Phase 1 CAR T-cell therapy leads to years-long remissions in relapsed B-cell lymphoma patients
A phase 1 clinical trial of chimeric antigen receptor (CAR) T-cell therapy, which involves re-engineering patients’ own immune cells to attack cancer cells, has demonstrated previously unheard of remissions of up to five years in relapsed B-cell...
Association of Measurable Residual Disease With Survival in Patients With Acute Myeloid Leukemia
This meta-analysis examines the use of measurable residual disease as an end point in studies to assess survival outcomes in patients with acute myeloid leukemia.
CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma
Purpose: CD19-specific chimeric antigen receptor (CAR)-T cell therapy is effective against refractory or relapsed (R/R) B-cell lymphoma, but the efficacy is hindered by the existence of PD-1/PD-L1 pathway. Experimental Design: Here we generated a...
FDA Approval Sought for Pacritinib in Myelofibrosis With Severe Thrombocytopenia
A rolling submission of a new drug application for the JAK2/FLT3 inhibitor pacritinib has been initiated for patients with myelofibrosis and severe thrombocytopenia defined as platelet counts of less than 50,000 μL.
FDA Grants Breakthrough Therapy Designation to IMGN632 in Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
The FDA has granted a breakthrough therapy designation to IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.
AAML1421 phase I/II trial of CPX-351 followed by FLAG, in children with R/R AML
The treatment and long-term survival of childhood acute myeloid leukemia (AML) is often complicated by the cardiotoxicity of anthracycline use. CPX-351 is a liposomal preparation of daunorubicin and cytarabine maintained at a 1:5 molar ratio that...
APR-246 plus azacitidine for patients with TP53 mutated MDS and AML
The GFM-APR trial is investigating the safety and efficacy of APR-246 plus AZA as maintenance therapy for patients with TP53 mutant AML or MDS following allo-SCT. Results were presented at this year’s virtual European Hematology Association (EHA)...
Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation | Blood Advances | American Society of Hematology
Key Points. Leukemic evolution of PV and ET harbored distinct molecular profiles associated with different time to transformation.Additional mutations in the c
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients | Blood Advances | American Society of Hematology
Key Points. This is the largest study describing the clinical features and outcomes, according to different therapeutic approaches, of patients with BPDCN.NHL-
Welcome! You are invited to join a webinar: Acute Leukaemia. After registering, you will receive a confirmation email about joining the webinar.
In this webinar, our key speakers will discuss the importance of early diagnosis and safety netting in acute leukaemia.
Audience: This webinar is suitable for primary care professionals across NHS England.
Key speakers:
• Dr Anit Patel, Consultant...
Omidubicel Meets All Secondary End Points of Phase 3 Trial in Hematologic Malignancies
The investigational advanced cell therapy omidubicel resulted in rapid platelet engraftment and reduced the number of infections and hospitalizations in patients with high-risk hematologic malignancies, meeting all 3 secondary end points of a phase...
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Single-cell transcriptomics reveals that the heterogeneity of anti-CD19 CAR T cell infusion products contributes to variability in clinical response, early molecular response and development of immune effector cell-associated neurotoxicity syndrome...